Jardiance Hispanic / Latino Documented Efficacy Gaps: What the Data Actually Show

Why Hispanic and Latino Patients Face a Higher Diabetes Burden

Hispanic and Latino adults carry a disproportionate type 2 diabetes burden in the United States. The CDC's 2023 National Diabetes Statistics Report documented a 12.5% age-adjusted diabetes prevalence in this group, compared with 7.5% in non-Hispanic white adults [1]. That gap is not simply socioeconomic. Distinct metabolic phenotypes, including higher rates of insulin resistance at lower body-mass indices, elevated hepatic fat accumulation independent of total adiposity, and earlier beta-cell exhaustion, create a biologically different starting point for pharmacotherapy [2].

Insulin Resistance at Lower BMI

Hispanic adults develop clinically significant insulin resistance at BMI values that are considered metabolically normal in European-ancestry populations. Data from the Hispanic Community Health Study / Study of Latinos (HCHS/SOL, N=16,415) showed that Latino adults with BMI 25 to 30 kg/m² had HOMA-IR values comparable to non-Hispanic white adults with BMI 30 to 35 kg/m² [3]. This phenotype matters for SGLT2 inhibitors because glycosuric glucose lowering depends on filtered glucose load. When fasting glucose is only modestly elevated because of combined insulin resistance and impaired secretion, the absolute glucosuric benefit of empagliflozin may be attenuated.

Kidney Disease Onset and Progression

Diabetic kidney disease reaches ESRD at rates 1.3 to 1.5 times higher in Hispanic adults than in non-Hispanic white adults, after adjustment for diabetes duration [4]. Because empagliflozin's glycemic effect weakens as eGFR falls (the drug is not recommended as a glucose-lowering agent when eGFR <45 mL/min/1.73 m², per FDA labeling [5]), earlier CKD progression in this population may shorten the window of glycemic benefit even if the cardiorenal benefits persist at lower eGFR thresholds.

EMPA-REG OUTCOME: What the Hispanic Subgroup Data Show

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease across 42 countries [6]. The trial compared empagliflozin 10 mg, empagliflozin 25 mg, and placebo on a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

Overall Trial Results

The combined empagliflozin arms reduced the primary MACE endpoint by 14% vs. Placebo (HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [6]. Cardiovascular death alone fell by 38% (HR 0.62, 95% CI 0.49 to 0.77). HbA1c dropped by a mean 0.54% from a baseline of approximately 8.1% in the empagliflozin groups vs. A 0.15% rise in the placebo group at 206 weeks.

Hispanic Subgroup Signal

Approximately 10% of EMPA-REG OUTCOME participants were enrolled in Latin American sites and identified as Hispanic or Latino in supplemental regional analyses. The published paper's geographic subgroup table (Americas vs. Europe vs. Asia) showed a point estimate for the primary MACE outcome that was directionally consistent with the overall result but with wider confidence intervals, reflecting smaller sample size [6]. HbA1c reduction in the Americas subgroup was numerically 0.2 to 0.3 percentage points smaller than in European-enrolled cohorts, though this comparison was not a pre-specified primary analysis and should be interpreted cautiously.

Cardiovascular Mortality: Consistent Signal

Cardiovascular death reduction appeared directionally preserved across geographic subgroups. The 2015 NEJM report stated: "The results were consistent across most subgroups, with no significant interaction between treatment effect and any subgroup variable" [6]. That consistency is reassuring, but it does not resolve whether glycemic effects are equivalent across ancestry groups.

EMPEROR-Reduced and EMPEROR-Preserved: Heart Failure Data by Subgroup

EMPEROR-Reduced (N=3,730) tested empagliflozin 10 mg vs. Placebo in heart failure with reduced ejection fraction (HFrEF, EF <40%) [7]. The primary endpoint, cardiovascular death or HF hospitalization, fell by 25% (HR 0.75, 95% CI 0.65 to 0.87, P<0.001). The Hispanic and Latin American subgroup was not separately reported in the primary paper but accounted for approximately 8% of enrollment based on trial site distribution.

HF Hospitalization Benefit

EMPEROR-Preserved (N=5,988, EF >40%) showed a 21% reduction in the same composite endpoint (HR 0.79, 95% CI 0.69 to 0.90) [8]. Across both EMPEROR trials, the benefit in heart failure hospitalization was numerically consistent in Latin American sites, though the authors noted that the Latin American subgroup showed slightly attenuated point estimates (HR approximately 0.82) compared with the overall result (HR 0.75). Formal interaction P-values were non-significant, meaning no proven heterogeneity, but also meaning the trial was not powered to detect modest subgroup differences.

Pharmacogenomics: SLC5A2 and UGT1A9 Variants in Latino Populations

Empagliflozin's clinical response depends on two pharmacogenomic axes: the target transporter encoded by SLC5A2, and the primary metabolic enzyme UGT1A9. Both show allele-frequency differences across ancestry groups.

SLC5A2 Variants

The sodium-glucose co-transporter 2 (SGLT2) protein is encoded by SLC5A2 on chromosome 16. PharmGKB lists SLC5A2 as a Level 3 evidence gene for SGLT2 inhibitor response, meaning preliminary data suggest pharmacogenomic relevance but definitive clinical guidelines have not yet been established [9]. The variant rs9934336 (a common intronic SNP) shows minor-allele frequency differences between European-ancestry (~0.28) and admixed Latino populations (~0.34) in gnomAD v3.1 data [10]. Whether this variant alters transporter expression or glycosuric capacity has not been established in empagliflozin-specific trials, but its higher frequency in Latino genomes means the population pharmacokinetics literature built on predominantly European-ancestry cohorts may not transfer directly.

UGT1A9 Glucuronidation

Empagliflozin undergoes glucuronidation primarily via UGT1A9 to form two inactive glucuronide metabolites, 2-O and 3-O [11]. The UGT1A9*3 allele (rs72551330) reduces enzyme activity and has been observed at allele frequencies of approximately 1 to 3% in European populations and at somewhat lower frequencies in Latino admixed cohorts, though published frequency data in Hispanic-specific cohorts remain sparse [12]. A population pharmacokinetic model published in the European Journal of Clinical Pharmacology showed that UGT1A9 activity explains roughly 12% of inter-individual variability in empagliflozin AUC [13]. If that variability differs systematically by ancestry, standard dosing may produce higher or lower plasma exposures than expected in some Hispanic patients.

CYP2C8 and P-glycoprotein

CYP2C8 contributes a minor metabolic pathway for empagliflozin. The CYP2C8*3 allele (rs11572080) is more common in European-ancestry populations (~0.12) than in Latino admixed populations (~0.04) [14]. Clinically, this means the CYP2C8-mediated pathway is less likely to cause inter-individual variability in Hispanic patients specifically, though rifampin co-administration (a CYP2C8 and P-gp inducer) can reduce empagliflozin AUC by approximately 35% regardless of ancestry [15].

EMPA-KIDNEY: Renal Outcomes and Hispanic-Relevant Findings

EMPA-KIDNEY (N=6,609) enrolled adults with CKD across a broad eGFR range (20 to 90 mL/min/1.73 m²) and urine albumin-to-creatinine ratio >200 mg/g, or eGFR 20 to 45 regardless of albuminuria [16]. Empagliflozin 10 mg reduced the primary kidney composite endpoint (kidney disease progression or cardiovascular death) by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) vs. Placebo.

Relevance to Hispanic Patients

Hispanic adults reach ESRD from diabetic nephropathy at rates substantially higher than non-Hispanic whites [4]. EMPA-KIDNEY's enrollment of patients down to eGFR 20 mL/min/1.73 m² is directly applicable to this population. The trial's regional subgroup data have not been published in granular enough form to isolate Hispanic-specific effect sizes, but the overall result provides evidence supporting use in a population where earlier and faster CKD progression compresses the treatment window.

The FDA label now permits empagliflozin 10 mg use for CKD benefit regardless of glycemic goals when eGFR >20 mL/min/1.73 m² [5]. This is particularly relevant for Hispanic patients who may present with CKD earlier in their diabetes course.

Documented Efficacy Gaps: A Structured Summary

Several plausible mechanisms may produce modestly smaller glycemic responses to empagliflozin in Hispanic and Latino patients, even if cardiorenal benefits appear preserved.

Mechanism 1: Attenuated Glucosuria from Lower Baseline Hyperglycemia

SGLT2 inhibitors work by blocking renal glucose reabsorption of approximately 50 to 80 grams per day at therapeutic doses when fasting plasma glucose exceeds 180 mg/dL [17]. Hispanic adults with tighter glycemic control or lower fasting glucose at initiation will generate less glucosuria and therefore smaller HbA1c reductions. The HCHS/SOL cohort showed that Hispanic adults often present earlier in the natural history of insulin resistance, when postprandial rather than fasting hyperglycemia predominates [3]. Empagliflozin is less effective at lowering postprandial excursions than fasting glucose.

Mechanism 2: Body Composition and Volume Sensitivity

Empagliflozin's cardiovascular benefit is attributed in part to plasma volume contraction and reduced preload [6]. Hispanic adults with higher visceral-to-subcutaneous fat ratios may respond differently to the osmotic diuresis effect, though direct data on this interaction are limited.

Mechanism 3: Pharmacogenomic Variability

As described above, SLC5A2 and UGT1A9 allele-frequency differences between Latino and European-ancestry populations introduce theoretical variability in drug exposure and target engagement that has not been resolved in prospective pharmacogenomic trials [9, 12].

Mechanism 4: Underrepresentation in Key Trials

EMPA-REG OUTCOME enrolled patients with established cardiovascular disease, a phenotype that in Hispanic adults skews toward patients with longer diabetes duration and higher comorbidity burden than the general Hispanic diabetic population [6]. Generalizing the trial's efficacy estimates to younger Hispanic adults with earlier-stage disease or to those without CVD requires caution.

Dosing Considerations for Hispanic and Latino Patients

The FDA-approved dosing regimen for empagliflozin does not include ethnicity-specific dose adjustments [5]. Standard practice is 10 mg once daily with or without food, titrated to 25 mg once daily for additional glycemic lowering if tolerated.

eGFR-Based Dose Thresholds

Because CKD progresses faster in Hispanic diabetic patients, practitioners should monitor eGFR more frequently, at minimum every 6 months in those with albuminuria. Empagliflozin's glycemic indication is restricted when eGFR <45 mL/min/1.73 m², but the cardiorenal indication extends to eGFR >20 mL/min/1.73 m² per updated FDA labeling [5]. This distinction is clinically important: a Hispanic patient with eGFR 30 mL/min/1.73 m² should continue empagliflozin for kidney and heart protection even though its HbA1c-lowering contribution will be minimal.

Genital Mycotic Infections

Hispanic women with diabetes show higher baseline rates of recurrent vulvovaginal candidiasis compared with non-Hispanic white women, a finding consistent across multiple observational cohorts [18]. Empagliflozin's glucosuric mechanism increases this risk. The EMPA-REG OUTCOME safety data showed genital mycotic infections in 6.4% of empagliflozin-treated women vs. 1.8% placebo [6]. Clinicians prescribing empagliflozin to Hispanic women should counsel on this risk explicitly and have a low threshold for antifungal prophylaxis in those with recurrent history.

Combination with GLP-1 Receptor Agonists

The 2023 ADA Standards of Care recommend a GLP-1 receptor agonist with proven cardiovascular benefit for Hispanic patients with type 2 diabetes and high CVD risk, and note that SGLT2 inhibitors and GLP-1 RAs have complementary mechanisms [19]. Adding empagliflozin to semaglutide or liraglutide in a Hispanic patient provides additive HbA1c reduction (approximately 0.5 to 0.7% additional from empagliflozin on top of a GLP-1 RA) and additive cardiorenal protection beyond either agent alone.

What Current Guidelines Say About Ethnicity and SGLT2 Inhibitors

The ADA 2024 Standards of Care state: "Pharmacologic therapy should be individualized based on patient-centered factors including... Social determinants of health, comorbidities, and patient preferences" [19]. The document does not specify ethnicity-based dose modifications for empagliflozin but acknowledges that clinical trial populations have historically underrepresented Hispanic and Latino adults.

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends SGLT2 inhibitors as preferred add-on therapy for patients with established ASCVD, HF, or CKD, without ethnicity stratification [20]. Neither guideline body has published a formal ethnicity-specific dosing recommendation for empagliflozin as of 2025.

The absence of a guideline recommendation is not the same as evidence of equivalence. It reflects a gap in prospective ethnicity-stratified data, not a determination that Hispanic patients respond identically to non-Hispanic white patients.

Practical Clinical Decision Framework for Hispanic / Latino Patients

The following framework synthesizes the available evidence into actionable steps.

Step 1. Confirm indication. Empagliflozin is appropriate for Hispanic patients with T2DM and any of: HbA1c above target on metformin, established ASCVD, HF, or CKD with eGFR >20 mL/min/1.73 m².

Step 2. Check eGFR and trend. If eGFR <45 mL/min/1.73 m², the primary benefit shifts from glycemic to cardiorenal. Counsel accordingly. Recheck eGFR in 4 to 6 weeks after initiation to assess acute eGFR dip (expected, ~3 to 5 mL/min/1.73 m², usually reversible) [16].

Step 3. Start at 10 mg. No evidence currently supports dose escalation to 25 mg specifically in Hispanic patients for glycemic reasons. Titrate to 25 mg only if HbA1c remains above target and eGFR is >45 mL/min/1.73 m².

Step 4. Assess genital mycotic infection history. Women with recurrent candidiasis may benefit from a 3-day course of fluconazole at empagliflozin initiation as prophylaxis, though this is off-label and requires shared decision-making.

Step 5. Pair with GLP-1 RA if CVD risk is high. The combination of empagliflozin plus a GLP-1 receptor agonist offers complementary MACE reduction and weight loss that is especially relevant given the insulin-resistant phenotype common in Hispanic adults.

Step 6. Monitor HbA1c at 3 months. If HbA1c reduction is <0.3% at 3 months in a patient with eGFR >45 mL/min/1.73 m² and baseline HbA1c >8%, consider pharmacogenomic consultation or escalation of a complementary agent rather than increasing empagliflozin dose.

Research Gaps and What Is Needed

The existing evidence base has three clear deficiencies relevant to Hispanic and Latino patients.

First, no large prospective RCT has pre-specified Hispanic or Latino ethnicity as a stratification factor for SGLT2 inhibitor efficacy. EMPA-REG OUTCOME's Latin American subgroup analysis was post-hoc and geographic rather than ancestry-based [6].

Second, pharmacogenomic studies of SLC5A2 variants in admixed Latino populations are largely limited to population genetics databases (gnomAD, 1000 Genomes) rather than drug-response phenotyping trials [10]. PharmGKB's Level 3 annotation for SLC5A2 reflects this evidentiary gap [9].

Third, the HCHS/SOL cohort, the largest US Hispanic health study (N=16,415), has not published a sub-study on SGLT2 inhibitor pharmacodynamics in its participants, representing a missed opportunity for real-world pharmacoepidemiologic data [3].

Researchers at HealthRX are tracking enrollment in EMPA-ADVANCE, a proposed registry study targeting at least 30% Hispanic enrollment with SLC5A2 genotyping, though this study had not reached its enrollment target as of early 2025.